Private company
Unity Biotechnology, Inc.
American pharmaceutical preparations company, incorporated in Delaware.
Last updated Oct 18, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2024
Financial statements
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | $04 | $05 | $4.8M6 | $236.0K3 | $03 | $03 | |
| Research and development | $58.9M7 | $71.0M4 | $67.3M5 | $38.4M6 | $36.9M3 | $20.1M3 | $13.0M3 |
| Operating income | -$79.5M7 | -$89.7M4 | -$93.9M5 | -$56.7M6 | -$57.6M3 | -$44.7M3 | -$31.2M3 |
| Interest | $04 | $1.3M5 | $3.2M6 | $3.6M3 | $2.5M3 | $03 | |
| Net income | -$76.4M7 | -$82.2M4 | -$93.8M5 | -$60.7M6 | -$44.5M3 | -$39.9M3 | -$26.0M3 |
| Earnings per share | -$18.455 | -$10.886 | -$4.683 | -$2.703 | -$1.543 | ||
| Earnings per share (diluted) | -$18.455 | -$10.886 | -$4.683 | -$2.703 | -$1.543 |
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Cash | $15.4M7 | $37.5M4 | $17.8M5 | $32.9M6 | $12.7M3 | $19.8M3 | $7.6M3 |
| Current assets | $173.0M11 | $129.5M7 | $100.9M4 | $90.5M5 | $96.5M6 | $46.6M3 | $24.3M3 |
| Total assets | $181.4M11 | $151.2M7 | $156.3M4 | $124.7M5 | $124.3M6 | $65.7M3 | $37.7M3 |
| Current liabilities | $16.6M11 | $17.2M7 | $14.5M4 | $16.6M5 | $19.6M6 | $7.8M3 | $9.3M3 |
| Long-term debt | $07 | $24.5M4 | $18.4M5 | $10.9M6 | $06 | ||
| Total liabilities | $20.7M11 | $30.5M7 | $73.4M4 | $65.1M5 | $68.3M6 | $37.3M3 | $31.2M3 |
| Shareholders’ equity | $160.7M4 | $120.7M5 | $82.9M6 | $59.6M3 | $56.1M3 | $28.4M3 | $6.5M3 |
| Shares outstanding | 42.4M shares11 | 47.2M shares7 | 53.3M shares4 | 6.3M shares5 | 14.2M shares6 | 16.8M shares3 | 16.9M shares3 |
Leadership
Who has led Unity Biotechnology, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
20202025
- Chief executive officerAnirvan Ghosh Apr 1, 2020 to now12
- Chief executive officerKeith R. Leonard May 2, 2018 to Feb 12, 202013
- PresidentCraig R. Jalbert Jul 17, 2025 to now14
- Chief financial officerLynne Marie Sullivan Sep 15, 2020 to now15
- Chief financial officerRobert C. Goeltz Ii. May 2, 2018 to Jun 24, 202016
Board members and other officers (21)
- Chief Medical OfficerFederico Grossi Jan 7, 2025 to now17
- OfficerAlexander Hieu Nguyen Mar 11, 2021 to May 12, 202318
- OfficerLynne Marie Sullivan Aug 4, 2020 to May 12, 202319
- OfficerAlexander Azoy Sep 15, 2020 to Sep 15, 202020
- Chief Scientific OfficerDan Marquess May 2, 2018 to Jun 24, 202021
- Chief Medical OfficerJamie Dananberg May 2, 2018 to Apr 3, 202322
- Corporate Secretary and GCTamara Tompkins May 2, 2018 to Jun 24, 202023
- Board memberYehia Hashad Mar 10, 2025 to now24
- Board memberCraig R. Jalbert Jul 17, 2025 to now14
- Board memberMichael P. Samar May 26, 2022 to now25
- Board memberAnirvan Ghosh Apr 1, 2020 to now12
- Board memberGilmore Neil O'Neill Dec 14, 2020 to now26
- Board memberCamille D. Samuels May 2, 2018 to now27
- Board memberDavid L. Lacey May 2, 2018 to Jun 22, 202028
- Board memberGraham K. Cooper May 2, 2018 to Jun 28, 202129
- Board memberKeith R. Leonard May 2, 2018 to now13
- Board memberKristina Burow May 2, 2018 to Jun 28, 202130
- Board memberPaul L. Berns May 2, 2018 to now31
- Board memberRobert Nelsen May 2, 2018 to Jun 22, 202032
- Board memberMargo R. Roberts Dec 4, 2018 to now33
- General counselAlexander Hieu Nguyen Mar 27, 2024 to now34
Former names
Timeline
Filings
244 filings to the SEC since October 2021: 5 annual reports, 11 quarterly reports, 52 major events, 98 insider forms, 12 large holders, 66 other. The latest 20:
- Jan 2, 202615-12G EDGAR
- Nov 14, 2025SCHEDULE 13G/A EDGAR
- Sep 26, 2025EFFECT EDGAR
- Sep 26, 2025EFFECT EDGAR
- Sep 26, 20258-K EDGAR
- Sep 25, 2025POS AM EDGAR
- Sep 25, 2025POS AM EDGAR
- Sep 19, 20258-K EDGAR
- Aug 25, 2025S-8 POS EDGAR
- Aug 25, 2025S-8 POS EDGAR
- Aug 25, 2025S-8 POS EDGAR
- Aug 25, 2025S-8 POS EDGAR
- Aug 25, 2025S-8 POS EDGAR
- Aug 25, 2025S-8 POS EDGAR
- Aug 25, 2025S-8 POS EDGAR
- Aug 25, 2025S-8 POS EDGAR
- Aug 25, 2025S-8 POS EDGAR
- Aug 25, 2025S-8 POS EDGAR
- Aug 11, 2025DEF 14A EDGAR
- Aug 1, 2025PRE 14A EDGAR
The 244 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 12 such filings since October 2021, the latest 10:
- Nov 14, 2025SCHEDULE 13G/A
- May 15, 2025SCHEDULE 13G/A
- Nov 14, 2024SC 13G/A
- Feb 14, 2024SC 13G/A
- May 10, 2023SC 13G/A
- Feb 14, 2023SC 13G
- Feb 9, 2023SC 13G/A
- Oct 11, 2022SC 13G/A
- Sep 12, 2022SC 13G/A
- Feb 14, 2022SC 13G/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14SEC EDGARCraig R. Jalbert, President
- 15
- 16
- 17
- 18SEC EDGARAlexander Hieu Nguyen, Officer
- 19SEC EDGARLynne Marie Sullivan, Officer
- 20SEC EDGARAlexander Azoy, Officer
- 21
- 22
- 23
- 24SEC EDGARYehia Hashad, Board member
- 25SEC EDGARMichael P. Samar, Board member
- 26SEC EDGARGilmore Neil O'Neill, Board member
- 27SEC EDGARCamille D. Samuels, Board member
- 28SEC EDGARDavid L. Lacey, Board member
- 29SEC EDGARGraham K. Cooper, Board member
- 30SEC EDGARKristina Burow, Board member
- 31SEC EDGARPaul L. Berns, Board member
- 32SEC EDGARRobert Nelsen, Board member
- 33SEC EDGARMargo R. Roberts, Board member
- 34